
==== Front
Sci Rep
Sci Rep
Scientific Reports
2045-2322
Nature Publishing Group UK London

39261513
71479
10.1038/s41598-024-71479-z
Article
Trimethylamine-N-oxide and 5-year mortality: the role of gut microbiota-generated metabolite from the CORE-Thailand cohort
Senthong Vichai 1
Kiatchoosakun Songsak 1
Wongvipaporn Chaiyasith 1
Phetcharaburanin Jutarop 23
Sritara Piyamitr 4
Phrommintikul Arintaya arintaya.p@cmu.ac.th

5
CORE InvestigatorsSritara Piyamitr 6
Yamwong Sukit 6
Srimahachota Suphot 7
Boonyaratavej Smonporn 7
Satitthummanid Sudarat 7
Lertsuwunseri Vorarit 7
Udol Kamol 8
Krittayaphong Rungroj 8
Boonyasirinant Thananya 8
Wongpraparut Nattawut 8
Rattanasumawong Kasem 9
Tiyanon Waraporn 10
Satirapoj Bancha 10
Suraamornkul Swangjit 11
Kanaderm Chanikarn 12
Porapakkham Pornwalee 12
Changsirikulchai Siribha 13
Hutayanon Pisit 14
Deerochanawong Chaicharn 15
Wongtheptien Wattana 16
Jai-aue Sasivimon 16
Maraprasertsak Mongkol 17
Laksomya Thanakorn 18
Paspitsanu Pailin 18
Phrommintikul Arintaya 19
Wongcharoen Wanwarang 19
Prasertwitayakij Narawudt 19
Buranapin Supawan 19
Watcharasaksilp Kanokwan 19
Phengtham Uthai 20
Chotechuang Yotsawee 20
Siriwattana Khanchai 21
Siriaree Kamonwan 21
Kositchaiwat Jitti 22
Dinchuthai Pakaphan 23
Sukanandachai Bancha 24
Simtharakaew Tanin 24
Wongvipaporn Chaiyasith 25
Kiatchoosakun Songsak 25
Tatsanaviva Pyatat 25
Senthong Vichai 25
Taweesangsuksakul Prawit 26
Suwanugsorn Saranyou 27
Cheewatanakornkul Sirichai 27
Suksuphew Sarawut 28
Dutsadeevettakul Somchai 29
Worasuwannarak Surapong 30

1 https://ror.org/03cq4gr50 grid.9786.0 0000 0004 0470 0856 Cardiovascular Unit, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
2 https://ror.org/03cq4gr50 grid.9786.0 0000 0004 0470 0856 Department of Systems Biosciences and Computational Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
3 https://ror.org/03cq4gr50 grid.9786.0 0000 0004 0470 0856 Khon Kaen University National Phenome Center, Khon Kaen University, Khon Kaen, Thailand
4 grid.10223.32 0000 0004 1937 0490 Cardiovascular Unit, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
5 https://ror.org/05m2fqn25 grid.7132.7 0000 0000 9039 7662 Cardiovascular Unit, Department of Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50002 Thailand
6 grid.10223.32 0000 0004 1937 0490 Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
7 https://ror.org/028wp3y58 grid.7922.e 0000 0001 0244 7875 Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
8 grid.10223.32 0000 0004 1937 0490 Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
9 https://ror.org/03ay8b853 grid.415092.b 0000 0004 0576 2645 Police General Hospital, Royal Thai Police, Bangkok, Thailand
10 https://ror.org/007h1qz76 grid.414965.b 0000 0004 0576 1212 Phramongkutklao Hospital, Bangkok, Thailand
11 https://ror.org/04evmpa20 grid.417203.3 BMA Medical College and Vajira Hospital, Bangkok, Thailand
12 https://ror.org/01t3emk15 grid.413637.4 0000 0004 4682 905X Central Chest Institute of Thailand, Bangkok, Thailand
13 https://ror.org/04718hx42 grid.412739.a 0000 0000 9006 7188 Faculty of Medicine, Srinakharinwirot University, Bangkok, Thailand
14 https://ror.org/002yp7f20 grid.412434.4 0000 0004 1937 1127 Faculty of Medicine, Thammasat University, Pathum Thani, Thailand
15 https://ror.org/0238gtq84 grid.415633.6 0000 0004 0637 1304 Rajavithi Hospital, Bangkok, Thailand
16 https://ror.org/01zrgk985 grid.477048.8 Chiangrai Prachanukroh Hospital, Chiangrai, Thailand
17 Phrae Hospital, Phrae, Thailand
18 https://ror.org/03e2qe334 grid.412029.c 0000 0000 9211 2704 Faculty of Medicine, Naresuan University, Phitsanulok, Thailand
19 https://ror.org/05m2fqn25 grid.7132.7 0000 0000 9039 7662 Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
20 https://ror.org/02ph01924 grid.477497.e 0000 0004 0388 645X Lampang Hospital, Lampang, Thailand
21 https://ror.org/05jwkar19 grid.477560.7 0000 0004 0617 516X Nakornping Hospital, Chiang Mai, Thailand
22 https://ror.org/027xnsa83 grid.415153.7 0000 0004 0576 179X Phrapokklao Hospital, Chanthaburi, Thailand
23 https://ror.org/01ff74m36 grid.411825.b 0000 0000 9482 780X Faculty of Medicine, Burapha University, Chon Buri, Thailand
24 https://ror.org/0152ray34 grid.416297.f 0000 0004 0388 8201 Maharat Nakhon Ratchasima Hospital, Nakhon Ratchasima, Thailand
25 https://ror.org/03cq4gr50 grid.9786.0 0000 0004 0470 0856 Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
26 grid.9786.0 0000 0004 0470 0856 Khon Kaen Hospital, Khon Kaen, Thailand
27 https://ror.org/0575ycz84 grid.7130.5 0000 0004 0470 1162 Faculty of Medicine, Prince of Songkla University, Songkla, Thailand
28 https://ror.org/05sgb8g78 grid.6357.7 0000 0001 0739 3220 The Institute of Medicine, Suranaree University of Technology, Nakhon Ratchasima, Thailand
29 https://ror.org/01znkr924 grid.10223.32 0000 0004 1937 0490 Golden Jubilee Medical Center, Mahidol University, Bangkok, Thailand
30 Pranangklao Hospital, Nonthaburi, Thailand
11 9 2024
11 9 2024
2024
14 2126425 4 2024
28 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
The gut microbiota metabolite trimethylamine-N-oxide (TMAO)—derived from dietary phosphatidylcholine—is mechanistically linked to cardiovascular disease (CVD) and increased cardiovascular risk. This study examined the relationship between fasting plasma TMAO levels and 5-year all-cause mortality in a cohort of patients at high risk of cardiovascular events (CORE-Thailand Registry). Of the 134 patients, 123 (92%) had established cardiovascular disease, and 11 (8%) had multiple risk factors. Fasting plasma TMAO levels were measured using nuclear magnetic resonance spectroscopy. Within this prospective cohort study, the median TMAO was 3.81 μM [interquartile range (IQR) 2.89–5.50 μM], with a mean age of 65 ± 11 years; 61% were men, and 39.6% had type II diabetes. Among 134 patients, 65 (49%) were identified as the high-TMAO group (≥ 3.8 μM), and 69 (51%) were identified as the low-TMAO group (< 3.8 μM). After a median follow-up of 58.8 months, the high-TMAO group was associated with a 2.88-fold increased mortality risk. Following adjustment for traditional risk factors, high-sensitivity cardiac troponin-T, estimated glomerular filtration rate, angiotensin-converting enzyme (ACEI), or angiotensin-receptor blocker (ARB) use, the high-TMAO group remained predictive of 5-year all-cause mortality risk (the high-TMAO vs. the low-TMAO group, adjusted hazard ratio 2.73, 95% CI 1.13–6.54; P = 0.025). Among Thai patients at high risk of cardiovascular events, increased plasma TMAO levels portended greater long-term mortality risk.

Keywords

Mortality risk
Gut microbiota
Trimethylamine-N-oxide
Asian
Subject terms

Biomarkers
Cardiology
issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

The incidence of Cardiovascular Disease (CVD) continues to increase, and it remains the leading cause of death worldwide1. Despite advances in medical treatment and aggressive risk factor modification, a decline in CVD-related mortality has been reported; however, the significant residual risk remains unacceptably high1. It is thus important to identify new proatherogenic biomarkers for predicting mortality, identifying poor prognosis in patients at high risk of cardiovascular (CV) events and potentially serving as targets for CVD prevention.

Increasing evidence supports the role of trimethylamine-N-oxide (TMAO)—a gut microbiota metabolite derived from dietary phosphatidylcholine (PC)—in the pathogenesis of CVD2–4. PC is a major dietary source of choline and carnitine, often found in red meat, egg yolks, and the liver5. The amount of dietary PC that lead to elevated plasma TMAO levels exhibits interindividual variability, based on factors such as gut microbiota composition, liver function, and overall diet. Generally, habitual consumption of foods high in PC, especially in combination with other factors that promote TMAO production (like low fiber intake or specific gut microbiota profiles), can contribute to higher TMAO levels6. The production of TMAO from dietary PC involves multiple steps. Gut bacteria play a crucial role by converting dietary PC components, such as choline, betaine, and carnitine, into trimethylamine (TMA). The TMA produced in the gut is absorbed into the bloodstream and transported to the liver, where it is oxidized by flavin-containing monooxygenase 3 (FMO3) enzymes to form TMAO. The role of gut microbiota in this process was confirmed in a study showing that plasma TMAO production during a dietary PC challenge was significantly reduced following suppression of the gut microbiota with broad-spectrum antibiotics5,7.

Elevated plasma TMAO levels have been associated with an increased risk of CV events, an independent predictor of subclinical myocardial damage, and a predictor of adverse CVD risk in several studies6,8–13.

However, the role of TMAO has limited data in Thai population and some conflicting data about prognification of TMAO in Asian heart failure patients14. The current study examined the relationship between fasting plasma TMAO levels and long-term mortality in Thai participants at high risk of CV events.

Subjects and methods

This was a multicenter, prospective, longitudinal cohort study of Thai patients with high atherosclerotic risk. Data were sourced from a cohort of patients at high risk of CV events recorded in the CORE-Thailand registry. The CORE-Thailand registry includes patients aged ≥ 45 years with established CVD (eCVD) as well as those with multiple risk factors (MRFs), as detailed in the previous publications15. Patients with eCVD included established coronary artery disease (CAD), stroke /transient ischemic attack (TIA), or peripheral artery disease (PAD) while patients with MRFs were defined as the presence of at least three atherosclerosis risk factors, including male > 55 years, female > 65 years, Type II diabetes mellitus (DM) or impaired fasting glucose, hypertension, dyslipidemia, chronic kidney disease (CKD) defined as presence of proteinuria + 1 or estimated glomerular filtration rate (eGFR) < 60 ml/min) and family history of premature CVD.

Our Registry had 9,390 patients. However, only 134 patients had TMAO data because only one center can do TMAO measurements. All-cause mortality at five years was tracked by electronic chart review and confirmed by telephone interviews, official hospital records, or death certificates. The median follow-up period was 58.8 months (IQR 46.7–59.9).

The Khon Kaen University Ethics Committee for Human Research approved the study protocol HE611011 and HE671143 per the Declaration of Helsinki.

Laboratory testing

After informed consent was obtained from all the participants, fasting blood samples were collected in EDTA tubes during the hospital visit. Samples were maintained at 4 °C, immediately processed, and frozen at -80 °C until analyzed. Routine laboratory tests were performed on samples using the Abbott Architec platform (Abbott Laboratories), and high-sensitivity cardiac troponin-T (hs-cTnT) was measured using a high-sensitivity (5th generation) assay on a Roche Cobas e411 platform (Roche Diagnostics, Basel, Switzerland). The eGFR was calculated using the diet modification in renal disease (MDRD) equation.

The plasma TMAO levels were determined using a nuclear magnetic resonance spectroscopy (NMR) spectrometer at 400 MHz (Bruker, USA). The Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence was employed to obtain spectra (recycle delay-90°-t1-90°-tm-90°-acquisition) over 64 scans with four dummy scans. Quantification was achieved using the concentration of a known reference signal (TSP) to determine the TMAO concentration. The NMR method to measure TMAO level was highly significant correlated with Mass spectrometry (MS) with R2 = 0.9816.

Statistical analysis

All statistical analyses were performed using SPSS version 28 (SPSS Inc., Chicago, IL, USA). Continuous data are presented as means (standard deviation) or medians (interquartile range) and compared using the Student’s t-test or non-parametric test (Mann–Whitney U Test), as appropriate. Categorical variables are presented as numbers (%) and were compared between the groups using the chi-square test. Based on previous studies8, using the median level of plasma TMAO in the studied population, a plasma TMAO ≥ 3.8 μM was defined as the high-TMAO group, and < 3.8 μM was defined as the low-TMAO group. Kaplan–Meier analysis with Cox proportional hazards regression was used for the time-to-event analysis to determine hazard ratios (HRs) and 95% CIs for 5-year all-cause mortality between the TMAO groups. Adjustments were made for individual traditional cardiovascular risk factors (age, male sex, body mass index, diabetes mellitus, dyslipidemia, hypertension, and smoking status), eCVD, eGFR, hs-cTnT and angiotensin-converting enzyme (ACEI) or angiotensin receptor blocker (ARB) use to predict all-cause mortality. Statistical significance was set at p < 0.05.

Results

Patient characteristics

The baseline characteristics of our study cohort were stratified according to the all-cause death status (Table 1). Overall, the mean age of the patients was 64 years; 61% were men. The median TMAO was 3.81 μM [interquartile range (IQR) 2.89–5.50]. Patients who died were older, received less beta blocker and had higher hs-cTnT level.Table 1 Baseline characteristics of study participants.

Variables	Overall (N = 134)	All cause death	P value	
Yes (N = 33)	No (N = 101)	
Age, (year)	64.05(8.9)	69.45(8.2)	62.29(8.3)	 < .001	
Male sex, (%)	82(61.2)	16(48.5)	66(65.3)	0.09	
BMI, (kg/m2), mean (± SD)	24.62(4.19)	23.79(3.79)	24.89(4.30)	0.19	
Systolic BP (mm Hg), mean (± SD)	131.49(19.45)	129.30(22.66)	132.20(18.35)	0.25	
Diastolic BP (mm Hg), mean (± SD)	73.1(9.52)	71.79(12.31)	71.79(12.32)	0.46	
Heart rate (beat per min), mean (± SD)	73.6(12.97)	77.97(15.97)	72.16(11.56)	0.06	
Coronary artery disease (%)	123(91.8)	30(90.9)	93(92.1)	0.83	
History of myocardial infarction (%)	99(73.9)	25(75.8)	74(73.3)	0.78	
Percutaneous coronary intervention (%)	100(74.6)	27 (81.0)	73(72.3)	0.14	
Coronary artery bypass graft surgery (%)	4(3.0)	2(2.6)	2(3.5)	0.98	
Diabetes mellitus (%)	53(39.6)	15(45.5)	38(37.6)	0.42	
Hypertension (%)	67(50.0)	18(55.0)	49 (49.0)	0.32	
Current smoker status, mean (± SD)	8 (6.0)	1 (3.0)	7 (6.9)	0.41	
hs-cTnT (ng/L), median (inter-quartile range)	15.65(10.17–26.67)	21.14(11.03–43.34)	14.59(9.49–23.76)	0.03	
Dyslipidemia (%)	53(39.6)	13(39.4)	40(39.6)	0.98	
eGFR (ml/min/1.73 m2), median (inter-quartile range)	72.4(51.7–88.55)	67.30(47.85–84.12)	72.84(52.06–89.35)	0.32	
Medication	
 Aspirin or Clopidogrel (%)	126(94)	33(100.0)	93(92.1)	0.09	
 ACEI or ARB (%)	85(63.4)	29(88.0)	56(56.0)	0.07	
 Statin (%)	131(97.8)	33(100.0)	98(97.0)	0.32	
 Beta-blockers (%)	109(81.3)	23(69.7)	86(85.1)	0.05	
TMAO ( μM ), median (inter-quartile range)	3.81(2.89–5.50)	4.72(3.39–8.31)	3.58(2.72–4.71)	0.004	
Established CVD (%)	123(91.8)	71 (92.2)	52 (91.2)	0.98	
Values are mean ± SD, %, or median (inter-quartile range).

ACEI  angiotensin converting enzyme inhibitors, ARB  angiotensin-receptor blocker, BMI  body mass index, BP  blood pressure, eGFR  estimated glomerular filtration rate, hs-cTnT high-sensitivity cardiac troponin T, TMAO trimethylamine N-oxide, CVD  cardiovascular disease.

Baseline fasting plasma TMAO levels and 5-year all-cause mortality

During the median follow-up duration of 58.8 months (IQR 46.7–59.9), 33 (24.6%) deaths occurred in our study cohort. Interestingly, the TMAO levels were significantly higher in patients who died than who survived [4.72 μM (3.39–8.31) vs. 3.58 μM (2.72–4.71), P = 0.004] (Fig. 1).Fig. 1 Baseline plasma TMAO levels between alive and dead patients at 5-year follow-up.

Figure 2 represents the Kaplan–Meier analysis of TMAO stratified by low (< 3.8 μM) or high-TMAO (≥ 3.8 μM) group, which illustrates a significantly increased risk for all-cause mortality in the high-TMAO group (log-rank, p = 0.007). Importantly, the high-TMAO group was associated with a significant 2.88-fold increased risk of all-cause mortality compared with the low-TMAO group (unadjusted HR 2.88, 95% CI 1.34–6.25, P = 0.007). The significant prognostic value in the high-TMAO group was preserved when adjusted for traditional risk factors (age, male sex, body mass index, diabetes mellitus, dyslipidemia, hypertension, and smoking status) and eCVD, eGFR, hs-cTnT , and ACEI or ARB use (adjusted HR 2.73, 95% CI 1.13–6.54, P = 0.025) (Table 2 and Table S1). In addition, after beta blocker use was added as a covariate, high-TMAO level remained an independent predictor of adverse cardiovascular events (adjusted HR 2.595, 95% CI 1.09–5.13, p = 0.03) (Table S2).Fig. 2 Kaplan–Meier estimated of risk of 5-year al-cause mortality between high-TMAO and low-TMAO group.

Table 2 Cox proportional hazards analyses of fasting plasma trimethylamine-N-oxide levels for 5-year all-cause mortality.

Model	Hazard ratio (95% confidence interval)	P value	
Unadjusted	2.88 (1.34–6.25)	0.007	
Adjusted	2.73 (1.13–6.54)	0.025	
High TMAO group (≥ 3.8 μM) versus low TMAO group (< 3.8 μM).

Adjusted for age, male, BMI, dyslipidemia, diabetes mellitus, hypertension, smoking, established CVD, eGFR, hs-cTnT and ACEI/ARB use (abbreviations as in Table 1).

Discussion

Our study demonstrated for the first time, that elevated fasting plasma TMAO levels at baseline provided strong prognostic information about 5-year all-cause mortality in Thai participants at high risk of cardiovascular events from the CORE-Thailand registry. The strong prognostic value was independent of traditional risk factors (age, male sex, body mass index, diabetes mellitus, dyslipidemia, hypertension, and smoking status), cardioprotective medication history (ACEI/ARB), marker of myocardial injury (hs-cTnT), and CVD status. The death rate was significantly higher in patients with higher baseline TMAO levels. The present findings support the incremental prognostic value of TMAO in stable patients at high risk of CV events (92% with eEAD and 8% with MRFs), which provides the opportunity to develop novel therapeutic strategies that target specific pathways of TMAO production and long-term prognosis.

The role of TMAO, a gut microbiota-generated metabolite, plays a vital role in human host metabolism and contributes to associated increased risk of diabetes, obesity, CKD, atherosclerosis, and long-term CVD morbidity and mortality3,6,12,13,17–19. These prognosis effects of elevated plasma TMAO were consistent with recent data from several clinical trials in subsets of patients with CAD, PAD, type II DM, CKD, history of heart failure, patients with suspected acute coronary syndrome initially negative for cTnT, and obesity 3,6,7,11,12,20,21. A study of 1,216 patients with type II DM who underwent elective coronary artery catheterization significantly increased the risk of 5-year mortality by up to 2.07-fold after adjustments for traditional risk factors and glycemic control17. Furthermore, elevated plasma TMAO levels can predict the presence of a high coronary atherosclerosis burden and a significant predictor of subclinical myocardial damage12,13,19. These findings are independent of traditional risk factors and other potentially confounding factors.

In the present study cohort, we defined TMAO ≥ 3.8 μM as the high-TMAO group because previous findings from independent study cohorts and meta-analyses showed that dose–response association between TMAO plasma levels and all-cause mortality begin at 3.8 μM8,10. Interestingly, elevated TMAO levels in the high-TMAO group vs. the low-TMAO group are a robust long-term prognostic predictor among patients at a high risk of CV events. Moreover, despite TMAO being cleared by the kidney, dose-dependent elevation in TMAO is noted in patients with CKD22. However, patients in the high-TMAO group remained an independent predictor of poor prognosis, even after adjusting for eGFR. Therefore, it is conceivable that significant residual CV risk may occur in patients with elevated plasma TMAO levels.

The mechanism of the relationship between TMAO and the increased risk of atherosclerosis and prediction of prognosis outcomes has been extensively investigated in real-world patients. Dietary nutrients that are rich in PC, the major dietary source of choline and carnitine (such as red meat), serve as precursors for TMA, which is converted into TMAO by FMO323. Several recent studies have demonstrated that FMO3 is an essential regulator of sterol and tissue cholesterol metabolism, prevents reverse cholesterol transport, and correlates with atherosclerotic plaque size in the arterial wall, which is linked to the development of atherosclerosis 5,23. In contrast, FMO3 knockdown mice showed decreased circulating TMAO levels and attenuated atherosclerotic plaque formation24. Interestingly, recent studies have found that vegans and vegetarians have lower plasma TMAO levels and fecal TMA/TMAO capacities than omnivores5. Significantly, diets rich in red meat or long-term exposure to oral L-carnitine are associated with higher plasma TMAO and TMA/TMAO-generating capacities in humans25,26. Moreover, TMAO has been shown to have direct biological activity in enhancing platelet hyperactivity, which increases the risk of thrombus formation and poor prognosis 27,28.

Thai cuisine typically features a combination of fresh herbs, spices, and aromatic ingredients such as lemongrass. In contrast, Western diets often include a wider use of dairy, wheat-based products, and a focus on individual flavors rather than complex combinations. However, in the urbanization era the diet pattern has been changed to westernized pattern29. The TMAO level in our study was in the same range with the western30.Our findings suggest that measurement of plasma TMAO levels among these high-risk patients should help identify those with residual CV risk, improve our understanding of the link between gut microbiota, TMAO, and long-term prognosis, and help select patients at a high risk of CV events who need more aggressive and specific interventions. Further studies are required to determine whether decreased TMAO with intervention, such as medication or probiotics, can improve the prognosis in patients at a high risk of CV events. Additionally, tissue concentrations of TMA and TMAO may differ from plasma levels, indicating the variable significance of the TMAO pathway across different organs and diseases31. Further studies are warranted.

Study limitations

This study recruited patients at high risk of CV events, mainly from tertiary care centers, and recruited only patients who had TMAO data; therefore, there was a higher proportion of patients with eCVD, and we cannot exclude the selection bias. As plasma TMAO was only analyzed once, we were unable to assess the prognostic significance of fluctuations in TMAO levels over time. The diet pattern such as amount of red meat which may associate with plasma TMAO level was not recorded. Despite these limitations, our findings provide a mechanistic link and strong prognostic information about 5-year all-cause mortality.

Conclusions

Elevated fasting plasma TMAO is an independent predictor of increased long-term mortality risk among patients at high risk of CV events.

Supplementary Information

Supplementary Information.

Abbreviations

CAD Coronary artery disease

CVD Cardiovascular disease

TMAO Trimethylamine-N-oxide

Supplementary Information

The online version contains supplementary material available at 10.1038/s41598-024-71479-z.

Acknowledgements

We thank Mr. Bryan Roderick Hamman—under aegis of the Publication Clinic KKU, Thailand—for assistance with the English-language presentation of the manuscript.

Author contributions

V.S. study conception and design, data collection, helped to run TMAO levels, analysis and interpretation of result, wrote the main manuscript and manuscript submitted. A.P. study conception and design, interpretation of result, revise manuscript, critical reading and final approval S.K., C.W. and P.S. critical reading J.P. critical reading and run TMAO levels.

Funding

This research was supported by the Heart Association of Thailand under the Royal Patronage of H.M. the King, National Research Council of Thailand and the Fundamental Fund of Khon Kaen University which has received funding support from the National Science, Research and Innovation Fund, Thailand (project number 67A103000113).

Data availability

The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

Competing interests

The authors declare no competing interests.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

A list of authors and their affiliations appears at the end of the paper.
==== Refs
References

1. Tsao CW Heart Disease and Stroke Statistics-2023 update: A report from the American Heart Association Circulation 2023 147 e93 e621 10.1161/cir.0000000000001123 36695182
Tsao, C. W. et al. Heart Disease and Stroke Statistics-2023 update: A report from the American Heart Association. Circulation 147, e93–e621. 10.1161/cir.0000000000001123 (2023).36695182 10.1161/cir.0000000000001123
2. Jonsson AL Bäckhed F Role of gut microbiota in atherosclerosis Nat. Rev. Cardiol. 2017 14 79 87 10.1038/nrcardio.2016.183 27905479
Jonsson, A. L. & Bäckhed, F. Role of gut microbiota in atherosclerosis. Nat. Rev. Cardiol. 14, 79–87. 10.1038/nrcardio.2016.183 (2017).27905479 10.1038/nrcardio.2016.183
3. Kanitsoraphan C Rattanawong P Charoensri S Senthong V Trimethylamine N-oxide and risk of cardiovascular disease and mortality Curr. Nutr. Rep. 2018 7 207 213 10.1007/s13668-018-0252-z 30362023
Kanitsoraphan, C., Rattanawong, P., Charoensri, S. & Senthong, V. Trimethylamine N-oxide and risk of cardiovascular disease and mortality. Curr. Nutr. Rep. 7, 207–213. 10.1007/s13668-018-0252-z (2018).30362023 10.1007/s13668-018-0252-z
4. Wang M Trimethylamine N-oxide is associated with long-term mortality risk: The multi-ethnic study of atherosclerosis Eur. Heart J. 2023 44 1608 1618 10.1093/eurheartj/ehad089 36883587
Wang, M. et al. Trimethylamine N-oxide is associated with long-term mortality risk: The multi-ethnic study of atherosclerosis. Eur. Heart J. 44, 1608–1618. 10.1093/eurheartj/ehad089 (2023).36883587 10.1093/eurheartj/ehad089
5. Koeth RA Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis Nat. Med. 2013 19 576 585 10.1038/nm.3145 23563705
Koeth, R. A. et al. Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat. Med. 19, 576–585. 10.1038/nm.3145 (2013).23563705 10.1038/nm.3145
6. Tang WHW Bäckhed F Landmesser U Hazen SL Intestinal microbiota in cardiovascular health and disease: JACC state-of-the-art review J. Am. Coll. Cardiol. 2019 73 2089 2105 10.1016/j.jacc.2019.03.024 31023434
Tang, W. H. W., Bäckhed, F., Landmesser, U. & Hazen, S. L. Intestinal microbiota in cardiovascular health and disease: JACC state-of-the-art review. J. Am. Coll. Cardiol. 73, 2089–2105. 10.1016/j.jacc.2019.03.024 (2019).31023434 10.1016/j.jacc.2019.03.024
7. Tang WH Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk N. Eng. J. Med. 2013 368 1575 1584 10.1056/NEJMoa1109400
Tang, W. H. et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N. Eng. J. Med. 368, 1575–1584. 10.1056/NEJMoa1109400 (2013).10.1056/NEJMoa1109400
8. Heianza Y Ma W Manson JE Rexrode KM Qi L Gut microbiota metabolites and risk of major adverse cardiovascular disease events and death: A systematic review and meta-analysis of prospective studies J. Am. Heart Assoc. 2017 10.1161/jaha.116.004947 28663251
Heianza, Y., Ma, W., Manson, J. E., Rexrode, K. M. & Qi, L. Gut microbiota metabolites and risk of major adverse cardiovascular disease events and death: A systematic review and meta-analysis of prospective studies. J. Am. Heart Assoc.10.1161/jaha.116.004947 (2017).28663251 10.1161/jaha.116.004947
9. Qi J Circulating trimethylamine N-oxide and the risk of cardiovascular diseases: A systematic review and meta-analysis of 11 prospective cohort studies J. Cell Mol. Med. 2018 22 185 194 10.1111/jcmm.13307 28782886
Qi, J. et al. Circulating trimethylamine N-oxide and the risk of cardiovascular diseases: A systematic review and meta-analysis of 11 prospective cohort studies. J. Cell Mol. Med. 22, 185–194. 10.1111/jcmm.13307 (2018).28782886 10.1111/jcmm.13307
10. Schiattarella GG Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: A systematic review and dose-response meta-analysis Eur. Heart J. 2017 38 2948 2956 10.1093/eurheartj/ehx342 29020409
Schiattarella, G. G. et al. Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: A systematic review and dose-response meta-analysis. Eur. Heart J. 38, 2948–2956. 10.1093/eurheartj/ehx342 (2017).29020409 10.1093/eurheartj/ehx342
11. Senthong V Trimethylamine N-oxide and mortality risk in patients with peripheral artery disease J. Am. Heart Assoc. 2016 10.1161/jaha.116.004237 27792653
Senthong, V. et al. Trimethylamine N-oxide and mortality risk in patients with peripheral artery disease. J. Am. Heart Assoc.10.1161/jaha.116.004237 (2016).27792653 10.1161/jaha.116.004237
12. Senthong V Intestinal microbiota-generated metabolite trimethylamine-N-oxide and 5-year mortality risk in stable coronary artery disease: The contributory role of intestinal microbiota in a COURAGE-like patient cohort J. Am. Heart Assoc. 2016 10.1161/jaha.115.002816 27792653
Senthong, V. et al. Intestinal microbiota-generated metabolite trimethylamine-N-oxide and 5-year mortality risk in stable coronary artery disease: The contributory role of intestinal microbiota in a COURAGE-like patient cohort. J. Am. Heart Assoc.10.1161/jaha.115.002816 (2016).27792653 10.1161/jaha.115.002816
13. Senthong V Gut microbiota-generated metabolite, trimethylamine-N-oxide, and subclinical myocardial damage: A multicenter study from Thailand Sci. Rep. 2021 11 14963 10.1038/s41598-021-93803-7 34294762
Senthong, V. et al. Gut microbiota-generated metabolite, trimethylamine-N-oxide, and subclinical myocardial damage: A multicenter study from Thailand. Sci. Rep. 11, 14963. 10.1038/s41598-021-93803-7 (2021).34294762 10.1038/s41598-021-93803-7
14. Yazaki Y Ethnic differences in association of outcomes with trimethylamine N-oxide in acute heart failure patients ESC Heart Fail. 2020 7 2373 2378 10.1002/ehf2.12777 32598563
Yazaki, Y. et al. Ethnic differences in association of outcomes with trimethylamine N-oxide in acute heart failure patients. ESC Heart Fail. 7, 2373–2378. 10.1002/ehf2.12777 (2020).32598563 10.1002/ehf2.12777
15. Phrommintikul A Management of atherosclerosis risk factors for patients at high cardiovascular risk in real-world practice: A multicentre study Singap. Med. J. 2017 58 535 542 10.11622/smedj.2017044
Phrommintikul, A. et al. Management of atherosclerosis risk factors for patients at high cardiovascular risk in real-world practice: A multicentre study. Singap. Med. J. 58, 535–542. 10.11622/smedj.2017044 (2017).10.11622/smedj.2017044
16. Garcia E NMR quantification of trimethylamine-N-oxide in human serum and plasma in the clinical laboratory setting Clin. Biochem. 2017 50 947 955 10.1016/j.clinbiochem.2017.06.003 28624482
Garcia, E. et al. NMR quantification of trimethylamine-N-oxide in human serum and plasma in the clinical laboratory setting. Clin. Biochem. 50, 947–955. 10.1016/j.clinbiochem.2017.06.003 (2017).28624482 10.1016/j.clinbiochem.2017.06.003
17. Tang WH Increased trimethylamine N-oxide portends high mortality risk independent of glycemic control in patients with type 2 diabetes mellitus Clin. Chem. 2017 63 297 306 10.1373/clinchem.2016.263640 27864387
Tang, W. H. et al. Increased trimethylamine N-oxide portends high mortality risk independent of glycemic control in patients with type 2 diabetes mellitus. Clin. Chem. 63, 297–306. 10.1373/clinchem.2016.263640 (2017).27864387 10.1373/clinchem.2016.263640
18. Gruppen EG TMAO is associated with mortality: impact of modestly impaired renal function Sci. Rep. 2017 7 13781 10.1038/s41598-017-13739-9 29061990
Gruppen, E. G. et al. TMAO is associated with mortality: impact of modestly impaired renal function. Sci. Rep. 7, 13781. 10.1038/s41598-017-13739-9 (2017).29061990 10.1038/s41598-017-13739-9
19. Senthong V Plasma trimethylamine N-oxide, a gut microbe-generated phosphatidylcholine metabolite, is associated with atherosclerotic burden J. Am. Coll. Cardiol. 2016 67 2620 2628 10.1016/j.jacc.2016.03.546 27256833
Senthong, V. et al. Plasma trimethylamine N-oxide, a gut microbe-generated phosphatidylcholine metabolite, is associated with atherosclerotic burden. J. Am. Coll. Cardiol. 67, 2620–2628. 10.1016/j.jacc.2016.03.546 (2016).27256833 10.1016/j.jacc.2016.03.546
20. Wang Z Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease Nature 2011 472 57 63 10.1038/nature09922 21475195
Wang, Z. et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472, 57–63. 10.1038/nature09922 (2011).21475195 10.1038/nature09922
21. Trøseid M Microbiota-dependent metabolite trimethylamine-N-oxide is associated with disease severity and survival of patients with chronic heart failure J. Intern. Med. 2015 277 717 726 10.1111/joim.12328 25382824
Trøseid, M. et al. Microbiota-dependent metabolite trimethylamine-N-oxide is associated with disease severity and survival of patients with chronic heart failure. J. Intern. Med. 277, 717–726. 10.1111/joim.12328 (2015).25382824 10.1111/joim.12328
22. Tang WH Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease Cir. Res. 2015 116 448 455 10.1161/circresaha.116.305360
Tang, W. H. et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Cir. Res. 116, 448–455. 10.1161/circresaha.116.305360 (2015).10.1161/circresaha.116.305360
23. Warrier M The TMAO-generating enzyme flavin monooxygenase 3 is a central regulator of cholesterol balance Cell Rep. 2015 10 326 338 10.1016/j.celrep.2014.12.036 25600868
Warrier, M. et al. The TMAO-generating enzyme flavin monooxygenase 3 is a central regulator of cholesterol balance. Cell Rep. 10, 326–338. 10.1016/j.celrep.2014.12.036 (2015).25600868 10.1016/j.celrep.2014.12.036
24. Shih DM Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis J. Lipid Res. 2015 56 22 37 10.1194/jlr.M051680 25378658
Shih, D. M. et al. Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis. J. Lipid Res. 56, 22–37. 10.1194/jlr.M051680 (2015).25378658 10.1194/jlr.M051680
25. Fukami K Oral l-carnitine supplementation increases trimethylamine-N-oxide but reduces markers of vascular injury in hemodialysis patients J. Cardio Pharmacol. 2015 65 289 295 10.1097/fjc.0000000000000197
Fukami, K. et al. Oral l-carnitine supplementation increases trimethylamine-N-oxide but reduces markers of vascular injury in hemodialysis patients. J. Cardio Pharmacol. 65, 289–295. 10.1097/fjc.0000000000000197 (2015).10.1097/fjc.0000000000000197
26. Miller MJ Chronic oral l-carnitine supplementation drives marked plasma TMAO elevations in patients with organic acidemias despite dietary meat restrictions JIMD Rep. 2016 30 39 44 10.1007/8904_2016_539 26936850
Miller, M. J. et al. Chronic oral l-carnitine supplementation drives marked plasma TMAO elevations in patients with organic acidemias despite dietary meat restrictions. JIMD Rep. 30, 39–44. 10.1007/8904_2016_539 (2016).26936850 10.1007/8904_2016_539
27. Li XS Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: A prognostic marker for incident cardiovascular events beyond traditional risk factors Eur. Heart J. 2017 38 814 824 10.1093/eurheartj/ehw582 28077467
Li, X. S. et al. Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: A prognostic marker for incident cardiovascular events beyond traditional risk factors. Eur. Heart J. 38, 814–824. 10.1093/eurheartj/ehw582 (2017).28077467 10.1093/eurheartj/ehw582
28. Zhu W Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk Cell 2016 165 111 124 10.1016/j.cell.2016.02.011 26972052
Zhu, W. et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell 165, 111–124. 10.1016/j.cell.2016.02.011 (2016).26972052 10.1016/j.cell.2016.02.011
29. Papier K Social demography of transitional dietary patterns in Thailand: Prospective evidence from the Thai Cohort Study Nutrients 2017 10.3390/nu9111173 29077031
Papier, K. et al. Social demography of transitional dietary patterns in Thailand: Prospective evidence from the Thai Cohort Study. Nutrients10.3390/nu9111173 (2017).29077031 10.3390/nu9111173
30. Heianza Y Long-term changes in gut microbial metabolite trimethylamine N-oxide and coronary heart disease risk J. Am. Coll. Cardiol. 2020 75 763 772 10.1016/j.jacc.2019.11.060 32081286
Heianza, Y. et al. Long-term changes in gut microbial metabolite trimethylamine N-oxide and coronary heart disease risk. J. Am. Coll. Cardiol. 75, 763–772. 10.1016/j.jacc.2019.11.060 (2020).32081286 10.1016/j.jacc.2019.11.060
31. Maksymiuk KM Mice, rats, and guinea pigs differ in FMOs expression and tissue concentration of TMAO, a gut bacteria-derived biomarker of cardiovascular and metabolic diseases PloS One 2024 19 e0297474 10.1371/journal.pone.0297474 38266015
Maksymiuk, K. M. et al. Mice, rats, and guinea pigs differ in FMOs expression and tissue concentration of TMAO, a gut bacteria-derived biomarker of cardiovascular and metabolic diseases. PloS One 19, e0297474. 10.1371/journal.pone.0297474 (2024).38266015 10.1371/journal.pone.0297474
